MFN2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL21045412	1.00	1/20
SCHEMBL22289758	1.00	1/20
SCHEMBL22620161	1.00	1/20
SCHEMBL27245326	1.00	1/20
SCHEMBL27245327	1.00	1/20
SCHEMBL22315339	0.86	1/20
SCHEMBL23766479	0.80	1/20
SCHEMBL22315361	0.77	1/20
SCHEMBL21082494	0.71	1/20
SCHEMBL21045408	0.70	1/20
SCHEMBL21045483	0.70	1/20
SCHEMBL20547946	0.69	1/20
SCHEMBL21045427	0.69	1/20
SCHEMBL30233690	0.69	1/20
SCHEMBL20547940	0.68	1/20
SCHEMBL23734079	0.68	1/20
SCHEMBL21045472	0.68	1/20
SCHEMBL21045551	0.68	1/20
SCHEMBL27028451	0.67	1/20
SCHEMBL27245325	0.67	1/20

Clinical trials — most relevant to MFN2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson's Patients	PHASE4	UNKNOWN
CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease	PHASE3	RECRUITING
Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy	PHASE3	RECRUITING
A Clinical Study to Evaluate the Safety of MF1, a New Treatment for Parkinson's Disease-related Disorders (MF1 Study)	PHASE1	RECRUITING
Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment	PHASE1	COMPLETED
Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D)	EARLY_PHASE1	COMPLETED
Mitoquines in COPD	nan	UNKNOWN
Paediatric Obesity and Cardiovascular Dysfunction	nan	COMPLETED
Dynamics of Muscle Mitochondria in Type 2 Diabetes Exercise	nan	COMPLETED
The Natural History of Mitochondrial Diseases	nan	RECRUITING
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Skeletal Muscle Regeneration in Survivors of Critical Illness: How to Prevent Satellite Cell Failure?	nan	RECRUITING
Ultrastructural Characteristics of Mitochondria in Cardiomyocytes in Heart Failure	nan	RECRUITING
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Insufficient Oxygenation in Septic Patients	nan	COMPLETED
Cardiac Mitochondrial Function in Explanted Human Hearts	nan	UNKNOWN
Exercise Training Effects on Muscle Function in Adults With Mitochondrial Myopathy	nan	RECRUITING
Mitochondrial Impairment in Muscle Insulin Resistance	nan	COMPLETED
Effect of Ketone Esters in Parkinson's Disease	nan	COMPLETED
Nicotinamide Riboside and Mitochondrial Biogenesis	nan	COMPLETED
Nicotinamide Levels in Serum, Aqueous Humor, and Tear Film in Glaucoma and Correlations With Mitochondrial Damage-Associated Molecular Patterns (mtDAMPs) and Senescence-Associated Secretory Phenotype (SASP)	nan	NOT_YET_RECRUITING
MITOMICS : a Multi-OMICS Approach for the Diagnosis of Mitochondrial Diseases	nan	RECRUITING
Combined Effects of Statins and Exercise on Training Sensitive Health Markers	nan	COMPLETED
Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19	nan	COMPLETED
Diagnostic Odyssey Survey 2	nan	COMPLETED
A Study Into the Underlying Biochemical Pathways Involved in Parkinson's Disease, Such as Mitochondrial (Cellular Powerhouse) Dysfunction	nan	COMPLETED
Mitochondrial Substrate Utilization in the Diabetic Human Heart	nan	RECRUITING
The Role of Muscle Protein Breakdown in the Regulation of Muscle Quality in Frail Elderly Individuals	nan	COMPLETED
Mitochondrial Video Assessment Source Material Study	nan	COMPLETED
Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a MFN2 binder may also engage these)

Protein	Name	Similarity
Q8R500	—	1.000	Q8R500 →
Q8R4Z9	—	1.000	Q8R4Z9 →
Q811U4	—	1.000	Q811U4 →
Q80U63	—	1.000	Q80U63 →
Q8IWA4	—	1.000	Q8IWA4 →
Q23424	—	0.998	Q23424 →
O18412	—	0.997	O18412 →
Q7YU24	—	0.994	Q7YU24 →
P93042	—	0.992	P93042 →
Q0JLS6	—	0.991	Q0JLS6 →
Q6XUX1	—	0.990	Q6XUX1 →
B6K0N7	—	0.990	B6K0N7 →
D4A770	—	0.990	D4A770 →
Q95KV0	—	0.989	Q95KV0 →
Q803H0	—	0.989	Q803H0 →
Q4VSN4	—	0.989	Q4VSN4 →
Q9NQ89	—	0.989	Q9NQ89 →
CHUK	Inhibitor of nuclear factor kappa-B kinase subunit alpha	0.989	landscape →
Q8WUM0	—	0.988	Q8WUM0 →
A2CI34	—	0.988	A2CI34 →
Q6GM53	—	0.988	Q6GM53 →
Q5PQS3	—	0.988	Q5PQS3 →
Q14D04	—	0.987	Q14D04 →
Q9Y3R5	—	0.987	Q9Y3R5 →
O93248	—	0.987	O93248 →
Q4TVR5	—	0.987	Q4TVR5 →
B8JKF4	—	0.987	B8JKF4 →
Q5BKL1	—	0.987	Q5BKL1 →
Q2KI89	—	0.987	Q2KI89 →
Q5F499	—	0.987	Q5F499 →